CSF3 and plasma cell myeloma: In mean 30.1 days (myeloma: 28.2 days; allogeneic: 31.9 days; p = 0.76) after the last G‐CSF administration, psychophysical assessment was repeated and showed a slightly enhanced threshold score for both study groups compared to T1 (myeloma: 8.9 ± 3.6 vs. 9.3 ± 3.3; allogeneic: 10.2 ± 3.5 vs. 11.8 ± 2.9; Figure 1; Table 1).